Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
Journal
Therapeutic Advances in Medical Oncology
Journal Volume
7
Journal Issue
5
Pages
274-290
Date Issued
2015
Author(s)
Abstract
Rearrangements in anaplastic lymphoma kinase (ALK) gene and echinoderm microtubule-associated protein-like 4 (EML4) gene were first described in a small portion of patients with non-small cell lung cancer (NSCLC) in 2007. Fluorescence in situ hybridization is used as the diagnostic test for detecting an EML4–ALK rearrangement. Crizotinib, an ALK inhibitor, is effective in treating advanced ALK-positive NSCLC, and the US Food and Drug Administration approved it for treating ALK-positive NSCLC in 2011. Several mechanisms of acquired resistance to crizotinib have recently been reported. Second-generation ALK inhibitors were designed to overcome these resistance mechanisms. Two of them, ceritinib and alectinib, were approved in 2014 for advanced ALK-positive NSCLC in the US and Japan, respectively. Heat shock protein 90 (Hsp90) inhibitors also showed activity against ALK-positive NSCLC. Here we review the recent development of crizotinib, ceritinib, alectinib and other second-generation ALK inhibitors as well as Hsp90 inhibitors. We also discuss management strategies for advanced ALK-positive NSCLC. ? 2015, SAGE Publications. All rights reserved.
SDGs
Other Subjects
2 [[2 (isopropylsulfonyl)phenyl]amino] 4 [[2 methoxy 4 [4 (4 methyl 1 piperazinyl) 1 piperidinyl]phenyl]amino] 1,3,5 triazine; 6 amino 5 [1 (2,6 dichloro 3 fluorophenyl)ethoxy] n [4 (4 methyl 1 piperazinylcarbonyl)phenyl] 3 pyridazinecarboxamide; alectinib; anaplastic lymphoma kinase; anaplastic lymphoma kinase inhibitor; cep 37440; ceritinib; crizotinib; entrectinib; ganetespib; luminespib; onalespib; pf 06463922; retaspimycin; tsr 011; unclassified drug; [2 [[5 chloro 2 [[4 [4 (dimethylamino) 1 piperidinyl] 2 methoxyphenyl]amino] 4 pyrimidinyl]amino]phenyl]dimethylphosphine oxide; advanced cancer; cancer resistance; cancer therapy; central nervous system metastasis; fluorescence in situ hybridization; food and drug administration; human; Japan; non small cell lung cancer; priority journal; Review; treatment outcome
Type
review